Skip to main content

ENGLISH · EVIDENCE OVERVIEW

PE-22-28
evidence profile

Spadin-derived heptapeptide / experimental TREK-1 inhibitor. This is a concise English overview, not a full translation. Read the evidence boundaries and original sources below; the detailed study and risk discussion remains available in Thai.

What do Class, Grade and Risk mean?

PE-22-28: conceptual scientific illustration for Neuro / Cognitive Research
VISUAL GUIDE · PE-22-28

Neuro / Cognitive Research

Category-level conceptual illustration, not a map of this molecule's receptor targets. It is not a treatment outcome and does not establish efficacy or safety.

QUICK ANSWER · AEO / GEO

PE-22-28 is a spadin-derived research heptapeptide studied for TREK-1 inhibition in cells and behavioural effects in mice. These findings do not establish rapid antidepressant efficacy, cognitive enhancement or human safety. Modified analogues must remain separate.

01

ENTITY FACTS

What should readers identify first?

MOLECULEPE-22-28
PHARMACOLOGYSpadin-derived heptapeptide / experimental TREK-1 inhibitor
PRIMECORE CLASSC
EVIDENCE GRADEE
RESEARCH TOPICNeuro / Cognitive Research
LAST REVIEWED2026-08-30

What remains unknown?

Insufficient data in the current dataset

What limits these conclusions?

English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty.

Read original excerpts (Thai / mixed language)
  • TREK-1 signal ≠ clinically proven antidepressant; ผลเร็วในหนูไม่กำหนดเวลาตอบสนองในคน

This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.

02

EVIDENCE BOUNDARY

What this overview does not establish

  • An evidence grade does not rank this molecule against another treatment.
  • A molecule name does not establish the identity, purity or regulatory status of a product.
  • Animal, cell or biomarker findings do not automatically establish human clinical benefit.
  • Approval in one country or indication does not transfer globally.

Where can I check the evidence?

Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.

  1. Primary study full text · PMC5601071
  2. Spadin-analogue study · PMID 28955242
03

FAQ · ANSWER ENGINE

Frequently asked questions

What is PE-22-28?

PE-22-28 is described pharmacologically as Spadin-derived heptapeptide / experimental TREK-1 inhibitor. PE-22-28 is a spadin-derived research heptapeptide studied for TREK-1 inhibition in cells and behavioural effects in mice. These findings do not establish rapid antidepressant efficacy, cognitive enhancement or human safety. Modified analogues must remain separate.

Does PE-22-28 have strong evidence?

PrimeCoreBio records Evidence Grade E. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.

Is PE-22-28 approved everywhere?

No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.

Medical Disclaimer

Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.

Contact PrimeCoreBio

Choose a contact channel

General information only · No sales or medical advice